Sino Biopharmaceutical Ltd Stock Performance
| SBHMY Stock | USD 9.05 0.00 0.00% |
On a scale of 0 to 100, Sino Biopharmaceutica holds a performance score of 7. The entity has a beta of 0.14, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Sino Biopharmaceutica's returns are expected to increase less than the market. However, during the bear market, the loss of holding Sino Biopharmaceutica is expected to be smaller as well. Please check Sino Biopharmaceutica's treynor ratio and day typical price , to make a quick decision on whether Sino Biopharmaceutica's existing price patterns will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Sino Biopharmaceutical Ltd are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent primary indicators, Sino Biopharmaceutica showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 10.6 B | |
| Total Cashflows From Investing Activities | -2.5 B | |
| Free Cash Flow | 3.5 B |
Sino |
Sino Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest 792.00 in Sino Biopharmaceutical Ltd on September 4, 2024 and sell it today you would earn a total of 113.00 from holding Sino Biopharmaceutical Ltd or generate 14.27% return on investment over 90 days. Sino Biopharmaceutical Ltd is currently producing 0.2401% returns and takes up 2.6762% volatility of returns over 90 trading days. Put another way, 23% of traded pink sheets are less volatile than Sino, and 96% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Sino Biopharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sino Biopharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Sino Biopharmaceutical Ltd, and traders can use it to determine the average amount a Sino Biopharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0897
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SBHMY | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.68 actual daily | 23 77% of assets are more volatile |
Expected Return
| 0.24 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Sino Biopharmaceutica is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sino Biopharmaceutica by adding it to a well-diversified portfolio.
Sino Biopharmaceutica Fundamentals Growth
Sino Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Sino Biopharmaceutica, and Sino Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sino Pink Sheet performance.
| Return On Equity | 0.29 | |||
| Return On Asset | 0.0451 | |||
| Profit Margin | 0.29 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 10.34 B | |||
| Shares Outstanding | 940.69 M | |||
| Price To Earning | 8.95 X | |||
| Price To Book | 2.53 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 26.86 B | |||
| EBITDA | 19.87 B | |||
| Cash And Equivalents | 15.67 B | |||
| Cash Per Share | 16.96 X | |||
| Total Debt | 5.21 B | |||
| Debt To Equity | 0.31 % | |||
| Book Value Per Share | 32.70 X | |||
| Cash Flow From Operations | 5.37 B | |||
| Earnings Per Share | 1.15 X | |||
| Total Asset | 60.54 B | |||
About Sino Biopharmaceutica Performance
Evaluating Sino Biopharmaceutica's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Sino Biopharmaceutica has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sino Biopharmaceutica has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the Peoples Republic of China. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong. Sino Biopharmaceutica is traded on OTC Exchange in the United States.Things to note about Sino Biopharmaceutical performance evaluation
Checking the ongoing alerts about Sino Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Sino Biopharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Evaluating Sino Biopharmaceutica's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Sino Biopharmaceutica's pink sheet performance include:- Analyzing Sino Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sino Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining Sino Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sino Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sino Biopharmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sino Biopharmaceutica's pink sheet. These opinions can provide insight into Sino Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Sino Pink Sheet Analysis
When running Sino Biopharmaceutica's price analysis, check to measure Sino Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sino Biopharmaceutica is operating at the current time. Most of Sino Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sino Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sino Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sino Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.